ULBP2 and B-cell chronic lymphocytic leukemia: The NKG2D receptor-ligand ULBP2 has been targeted by TriKEs (ULBP2/aCD19/aCD19 and ULBP2/aCD19/aCD33) and has demonstrated in vitro and in vivo activity against CLL [89].